Seeking Alpha News (Thu, 24-Sep 6:03 AM ET)
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Seeking Alpha News (Wed, 23-Sep 2:33 PM ET)
Gene editing stocks fall after report on Anthropic’s CRISPR-like discovery
Seeking Alpha News (Wed, 23-Sep 2:33 PM ET)
These four healthcare stocks have held Strong Buy ratings for 60+ days
Seeking Alpha News (Wed, 23-Sep 9:10 AM ET)
PRNewswire (Mon, 21-Sep 9:16 AM ET)
PRNewswire (Mon, 14-Sep 6:59 AM ET)
Q32 Bio to Participate in Upcoming September Investor Conferences
PRNewswire (Tue, 1-Sep 7:00 AM ET)
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PRNewswire (Wed, 5-Aug 6:59 AM ET)
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
PRNewswire (Tue, 14-Jul 10:59 PM ET)
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
PRNewswire (Mon, 13-Jul 4:01 PM ET)
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Q32 Bio trades on the NASDAQ stock market under the symbol QTTB.
As of September 25, 2026, QTTB stock price declined to $8.94 with 173,460 million shares trading.
QTTB has a beta of -1.87, meaning it tends to be less sensitive to market movements. QTTB has a correlation of 0.03 to the broad based SPY ETF.
QTTB has a market cap of $266.14 million. This is considered a Small Cap stock.
Last quarter Q32 Bio reported $0 in Revenue and -$.44 earnings per share. This fell short of revenue expectation by $-600,000 and exceeded earnings estimates by $.12.
The top ETF exchange traded funds that QTTB belongs to (by Net Assets): VTI, AVUV, VXF, FDM, DFAS.
QTTB has outperformed the market in the last year with a return of +378.1%, while the SPY ETF gained +17.9%. However, in the most recent history, QTTB shares have underperformed the stock market with its stock returning -19.9% in the last 3 month period and -16.6% for the last 2 week period, while SPY has returned +5.5% and +2.1%, respectively.
QTTB support price is $8.83 and resistance is $9.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTTB shares will trade within this expected range on the day.
